Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 3
2018 6
2019 13
2020 15
2021 26
2022 16
2023 12
2024 11
2025 11
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kazuhiro yamaguchi[Author] (86 results)?
Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.
Ikeda S, Ogura T, Misumi T, Nishioka Y, Hashimoto S, Ichikado K, Fukuizumi A, Takata S, Itoh T, Sato Y, Okishio K, Yatera K, Sakamoto N, Kato M, Kikuchi R, Honda T, Hashimoto N, Murakami K, Isshiki T, Yamane M, Karayama M, Miyamoto A, Ishida Y, Inomata M, Nishikiori H, Yamaguchi K, Amimoto H, Tamura K, Yanagihara T, Tanino Y, Koyama J, Tsurumaki N, Waseda Y, Kishaba T, Ozasa H, Matsumoto M, Kinoshita Y, Nakamura Y, Yamauchi H, Kishi K. Ikeda S, et al. Among authors: yamaguchi k. Eur J Cancer. 2026 Feb 25;235:116232. doi: 10.1016/j.ejca.2026.116232. Epub 2026 Jan 12. Eur J Cancer. 2026. PMID: 41539179
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita M, Ito K, Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Murata Y, et al. Among authors: yamaguchi k. JTO Clin Res Rep. 2023 Oct 20;4(12):100593. doi: 10.1016/j.jtocrr.2023.100593. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046378 Free PMC article.
The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
Yamaguchi K, Takao S, Kanaji N, Hirakawa T, Matsumoto N, Miyazaki K, Okimoto T, Ando C, Higo H, Yanai M, Nagasaki Y, Kurose K, Watanabe M, Oyama K, Toyoda Y, Ono S, Tada S, Iwamoto H, Hattori N. Yamaguchi K, et al. Eur J Cancer. 2025 Aug 26;226:115606. doi: 10.1016/j.ejca.2025.115606. Epub 2025 Jul 5. Eur J Cancer. 2025. PMID: 40639019 Free article.
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Kinoshita F, Fujishita T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Ishikawa N, Kozuki T, Kawamura T, Saito G, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Nishii K, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Tanzawa S, et al. Among authors: yamaguchi k. Ther Adv Med Oncol. 2025 Feb 14;17:17588359251318850. doi: 10.1177/17588359251318850. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39957806 Free PMC article.
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Kinoshita F, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Yamaguchi M, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Yamamoto K, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Kinoshita F, et al. Among authors: yamaguchi k. Ther Adv Med Oncol. 2025 Mar 15;17:17588359241312503. doi: 10.1177/17588359241312503. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40093977 Free PMC article.
106 results